Koers Pluristem Therapeutics Inc. Nasdaq
Aandelen
US72940R1023
Biotechnologie & Medisch Onderzoek
Omzet 2022 | 234K 215K | Omzet 2023 | 287K 263K | Marktkapitalisatie | 32,98 mln. 30,26 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -41 mln. -37,62 mln. | Nettowinst (verlies) 2023 | -28 mln. -25,69 mln. | EV/omzet 2022 | 58 x |
Nettoliquiditeiten 2022 | 26,21 mln. 24,05 mln. | Nettoliquiditeiten 2023 | 10,27 mln. 9,42 mln. | EV/omzet 2023 | 79,1 x |
K/w-verhouding 2022 |
-0,96
x | K/w-verhouding 2023 |
-1,04
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 78,02% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Yaky Yanay
CEO | Chief Executive Officer | 53 | 01-11-06 |
Director of Finance/CFO | 40 | 01-05-13 | |
Zami Aberman
CHM | Chairman | 70 | 26-09-05 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 73 | 15-07-21 | |
Zami Aberman
CHM | Chairman | 70 | 26-09-05 |
Yaky Yanay
CEO | Chief Executive Officer | 53 | 01-11-06 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+25,83% | 46,56 mld. | |
+45,38% | 41,67 mld. | |
+0,69% | 41,16 mld. | |
+30,52% | 32,4 mld. | |
+22,30% | 28,18 mld. | |
-6,35% | 28,1 mld. | |
+49,25% | 14,52 mld. | |
+49,18% | 13,74 mld. | |
+3,45% | 12,17 mld. |